N-甲基-2-(1-哌嗪)苯胺 | 96221-86-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: N-甲基-2-(1-哌嗪)苯胺
• 中文别名: N-甲基-2-(1-哌嗪基)苯胺
• 英文名称: N-methyl-2-(piperazin-1-yl)aniline
• 英文别名: 1-(2-methylaminophenyl)piperazine；1-[2-(methylamino)phenyl]piperazine；N-Methyl-2-piperazin-1-ylaniline
• CAS: 96221-86-2
• 化学式: C₁₁H₁₇N₃
• 分子量: 191.276
• InChiKey: FDZXJVNEJMPIHD-UHFFFAOYSA-N

物化性质

• 沸点：
  352℃
• 密度：
  1.079
• 闪点：
  197℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  27.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-甲基-2-(1-哌嗪)苯胺 、 3-环己基丙酰氯 在 三乙胺 作用下， 以 甲苯 为溶剂， 生成 1-(2-Methylamino-phenyl)-4-(3-cyclohexylpropionyl)-piperazine
  参考文献：
  名称：

  Oepen; Bork; Jakovlev, Arzneimittel-Forschung/Drug Research, 1988, vol. 38, # 11, p. 1549 - 1552

  摘要：

  DOI：

文献信息

• Piperazine derivatives and methods for the preparation thereof and
  申请人：Samjin Pharmaceuticazl Co., Ltd.

  公开号：US05780472A1

  公开（公告）日：1998-07-14

  The present invention relates to novel compound of the general formula(I) and acid addition salt thereof. ##STR1## wherein R.sub.1 and R.sub.2 are independently hydrogen, C.sub.1 -C.sub.8 alkyl or optionally substituted C.sub.3 -C.sub.6 membered cycloalkyl containing C.sub.3 -C.sub.8 ; R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are independently hydrogen, halogen, hydroxy, nitro, C.sub.1 -C.sub.4 lower ester, C.sub.1 -C.sub.4 lower alkyl, C.sub.1 -C.sub.4 lower alkoxy, aryl, arylalkoxy or unsaturated amine; l is an integer of 0-7; m and n are independently an integer of 0-1; W is carbon or nitrogen; X is oxygen, sulfur, optionally substituted imine; Y is nitrogen or oxygen; and Z is hydrogen, C.sub.1 -C.sub.8 alkoxy, aryloxy, C.sub.1 -C.sub.4 alkylamine, cycloamine containing N.sub.1 -N.sub.5 or oxo group. The present compounds of the above formula (I) has no only strong antimumor activities but lower toxicities, and accordingly are expected as novel antitumor agents.

  本发明涉及一般式(I)的新化合物及其酸盐。其中R.sub.1和R.sub.2独立地是氢、C.sub.1-C.sub.8烷基或可选择取代的含有C.sub.3-C.sub.6的C.sub.3-C.sub.8环烷基；R.sub.3、R.sub.4、R.sub.5、R.sub.6和R.sub.7独立地是氢、卤素、羟基、硝基、C.sub.1-C.sub.4较低酯基、C.sub.1-C.sub.4较低烷基、C.sub.1-C.sub.4较低烷氧基、芳基、芳基氧基或不饱和胺基；l是0-7的整数；m和n独立地是0-1的整数；W是碳或氮；X是氧、硫、可选择取代的亚胺；Y是氮或氧；Z是氢、C.sub.1-C.sub.8烷氧基、芳氧基、C.sub.1-C.sub.4烷基胺、含N.sub.1-N.sub.5的环胺或氧代基。上述一般式(I)的化合物具有强抗肿瘤活性和较低毒性，因此被期望作为新型抗肿瘤药物。
• ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF
  申请人：Shipps, JR. Gerald W.

  公开号：US20120328691A1

  公开（公告）日：2012-12-27

  The present invention relates to novel Anilinopiperazine Derivatives of Formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, cancer, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase.

  本发明涉及式（I）的新型苯胺哌嗪衍生物，包含该苯胺哌嗪衍生物的组合物，以及使用该苯胺哌嗪衍生物治疗或预防增生性疾病、癌症、抗增生性疾病、炎症、关节炎、中枢神经系统疾病、心血管疾病、脱发、神经疾病、缺血性损伤、病毒性疾病、真菌感染或与蛋白激酶活性相关的疾病的方法。
• Synthesis and evaluation of arylpiperazines derivatives of 3,5-dioxo-(2 H ,4 H )-1,2,4-triazine as 5-HT 1A R ligands
  作者：J.S. Dileep Kumar、Vattoly J. Majo、Jaya Prabhakaran、J. John Mann

  DOI：10.1016/j.bmcl.2014.07.048

  日期：2014.10

  5-HT1AR agonist or partial agonists are established drug candidates for psychiatric and neurological disorders. We have reported the synthesis and evaluation of a series of high affinity 5-HT1AR partial agonist PET imaging agents with greater selectivity over α-1AR. The characteristic of these molecules are 3,5-dioxo-(2H,4H)-1,2,4-triazine skeleton tethered to an arylpiperazine unit through an alkyl side chain. The most potent 5-HT1AR agonistic properties were found to be associated with the molecules bearing C-4 alkyl group as the linker. Therefore development of 3,5-dioxo-(2H,4H)-1,2,4-triazine bearing arylpiperazine derivatives may provide high affinity selective 5-HT1AR ligands. Herein we describe the synthesis and evaluation of the binding properties of a series of arylpiperazine analogues of 3,5-dioxo-(2H,4H)-1,2,4-triazine.
• Novel potent neuropeptide Y Y5 receptor antagonists: Synthesis and structure–activity relationships of phenylpiperazine derivatives
  作者：Toshiyuki Takahashi、Aya Sakuraba、Tomoko Hirohashi、Takunobu Shibata、Masaaki Hirose、Yuji Haga、Katsumasa Nonoshita、Tetsuya Kanno、Junko Ito、Hisashi Iwaasa、Akio Kanatani、Takehiro Fukami、Nagaaki Sato

  DOI：10.1016/j.bmc.2006.07.023

  日期：2006.11

  A series of phenylpiperazine derivatives were synthesized and evaluated for their neuropeptide Y (NPY) Y5 receptor antagonistic activities. The benzindane portion of 2 was replaced by I-phenylpiperazine, resulting in novel urea derivative X Subsequent optimization of the phenylpiperazine template by substitution of the phenyl moiety resulted in a series of (2-methanesulfonamidephenyl)piperazine derivatives that showed potent binding affinity and antagonistic activity for the Y5 receptor. (c) 2006 Elsevier Ltd. All rights reserved.
• Structure−Activity Relationship Study on <i>N</i>-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a Class of 5-HT₇ Receptor Agents. 2
  作者：Marcello Leopoldo、Enza Lacivita、Marialessandra Contino、Nicola A. Colabufo、Francesco Berardi、Roberto Perrone

  DOI：10.1021/jm070487n

  日期：2007.8.1

  Here we report the synthesis of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides 16-29 that were designed to elucidate both structure-affinity and -activity relationships for the 5-HT7 receptor, by targeting the substituent in 2-position of the aryl linked to the piperazine ring. The affinities of 16-29 for 5-HT7, 5-HT1A, 5-HT2A, and D-2 receptors were assessed by radioligand binding assays. The intrinsic activities at the 5-HT7 receptor of the most potent compounds were determined. A series of substituents covering a wide range of electronic, steric, and polar properties was evaluated, revealing a key role on 5-HT7 receptor affinity and intrinsic activity. Certain lipophilic substituents (SCH3, CH(CH3)(2), N(CH3)(2), CH3, Ph) led to high-affinity agonists, whereas OH and NHCH3 substituents switched intrinsic activity toward antagonism. 4-[2-(1-Methylethyl)phenyl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (19), 4-(2-diphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (21), and 4-(2-dimethylaminophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (22) were identified as potent 5-HT7 receptor agonists (K-i = 0.13-1.1 nM, EC50 = 0.90-1.77 mu M), showing selectivity over 5-HT1A, 5-HT2A, and D-2 receptors.